Abstract
Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
